Comparing the current results to its competitors, Exicure Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 0.35 %, recorded in the same quarter.
Exicure Inc 's Comment on Competition and Industry Peers
The company has historically competed with large and small biotechnology firms, academic institutions, government agencies, and public and private research organizations. These competitors possessed greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Competition also extended to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. After restructuring in September 2022, the company no longer has manufacturing or supply requirements.
September 18, 2024
Exicure, Inc. Receives Nasdaq Hearing Panel Extension Amidst Financial Challenges and Improved ROA RankingExicure, Inc. recently announced that it has received an extension from the Nasdaq Hearings Panel as the company navigates significant financial challenges. For the 12 months ending in the second quarter of 2024, Exicure recorded a cumulative net loss of $8 million, leading to a troubling return on assets (ROA) of -71.17%. This stark figure indicates that the company has not only struggled to generate profits but operates at a considerable loss relative to its asset base.In context, this negative ROA places Exicure in a precarious position within the broader Healthcare sector, where 427 other companies ...
May 24, 2024
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The notice was issued due to the company s failure to file its Form 10-K for the year ended December 31, 2023, in accordance with Nasdaq Listing Rule 5250(c)(1). This article aims to explore the implications of this delisting determination for Exicure, its current financial situation, and potential strategies the company might adopt to address this issue.Delisting Determination Notice:The Staff Delisting Determination sent to Exicure by Nasdaq highlighted the non-compliance with the Nasdaq ...
February 5, 2024
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisCHICAGO - Exicure, Inc. (NASDAQ:XCUR), a renowned developer of nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company specializing in viral and liver diseases, have recently announced a significant collaboration. The two companies have entered into a patent license agreement with the aim of developing cavrotolimod as a potential treatment for hepatitis.Hepatitis is a prevalent and serious condition affecting millions of individuals worldwide. While several advancements have been made in treating different types of hepatitis...
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
PTC Therapeutics Inc's business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.
Prothena Corporation Public Limited Company Share Performance
-8.21%
This Year
Prothena Corporation Public Limited Company
Profile
Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Exicure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Exicure Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
